Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003268 · ClinicalTrials.gov registry record · Phase 1
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1 study of Leukemia and Drug/Agent Toxicity by Tissue/Organ, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00003268 is a Phase 1 study of Leukemia and Drug/Agent Toxicity by Tissue/Organ that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The trial reports 1 study location across 1 state.
The verdict
NCT00003268, a Phase 1 study of Leukemia and Drug/Agent Toxicity by Tissue/Organ, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of amifostine in treating patients with newly diagnosed acute myeloid leukemia who are receiving idarubicin plus cytarabine.
Conditions Studied
Interventions
- DRUG cytarabine
- DRUG idarubicin
- DRUG amifostine trihydrate
Study Locations (1)
Pennsylvania
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-01 |
| Est. Completion | 2003-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003268
The ClinicalTrials.gov registry entry for NCT00003268 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which cytarabine is the first listed.
NCT00003268 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00003268 about?
NCT00003268 is a clinical study titled "Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I...
What is the current status of trial NCT00003268?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-01. Estimated completion is 2003-12.
What conditions does trial NCT00003268 study?
This clinical trial studies the following conditions: Leukemia, Drug/Agent Toxicity by Tissue/Organ.
What interventions are being tested in trial NCT00003268?
The interventions under investigation include: cytarabine (DRUG), idarubicin (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003268?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003268 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.